(Q34730748)

4 August 2017

1 reference

title

Generalised anxiety disorder: treatment options (English)

1 reference

4 August 2017

1 reference

John J Sramek

1

1 reference

4 August 2017

Victoria Zarotsky

series ordinal

2

1 reference

4 August 2017

Neal R Cutler

series ordinal

3

1 reference

4 August 2017

1 January 2002

1 reference

4 August 2017

1 reference

4 August 2017

62

1 reference

4 August 2017

1635-1648

1 reference

4 August 2017

11

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200262110-00005

4 August 2017

0 references

cites work

Safety and tolerability of CI-979 in patients with Alzheimer's disease

1 reference

12 December 2020

A controlled trial of treatments for generalized anxiety

1 reference

12 December 2020

Psychotherapy for generalized anxiety disorder.

1 reference

12 December 2020

Challenges in medication clinical trials

1 reference

12 December 2020

Placebo response in anxiety disorders

1 reference

12 December 2020

Risks and benefits of long-term benzodiazepine use.

1 reference

12 December 2020

Zopiclone, the third generation hypnotic: a clinical overview

1 reference

12 December 2020

A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder

1 reference

12 December 2020

The nonpharmacologic treatment of generalized anxiety disorder

1 reference

12 December 2020

High-affinity partial agonist imidazo[1,5-a]quinoxaline amides, carbamates, and ureas at the gamma-aminobutyric acid A/benzodiazepine receptor complex.

1 reference

12 December 2020

Early placebo response in anxious and depressed patients

1 reference

12 December 2020

Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Comparative behavioural profiles of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in the murine elevated plus-maze

1 reference

12 December 2020

Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) and the full agonist 6-(benzyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (Zk 9

1 reference

12 December 2020

Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients.

1 reference

12 December 2020

Benzodiazepine abuse in patients of doctors in domiciliary practice in the Basle area.

1 reference

12 December 2020

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

1 reference

12 December 2020

Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurones

1 reference

12 December 2020

Comorbidity in a clinical sample of substance abusers

1 reference

12 December 2020

Defining the maximum tolerated dose: investigator, academic, industry and regulatory perspectives

1 reference

12 December 2020

A meta-analysis of the effects of venlafaxine on anxiety associated with depression.

1 reference

12 December 2020

Psychiatric disorders among drug dependent subjects: are they primary or secondary?

1 reference

12 December 2020

The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease.

1 reference

12 December 2020

Discontinuation reactions to alprazolam in panic disorder

1 reference

12 December 2020

Overview of antidepressants currently used to treat anxiety disorders

1 reference

12 December 2020

A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder

1 reference

12 December 2020

A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase

1 reference

12 December 2020

Drug therapy. Current status of benzodiazepines

1 reference

12 December 2020

Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study

1 reference

12 December 2020

Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms

1 reference

12 December 2020

Efficacy trial of the 5-HT2 antagonist MDL 11,939 in patients with generalized anxiety disorder

1 reference

12 December 2020

Establishing the maximum tolerated dose of lesopitron in patients with generalized anxiety disorder: a bridging study

1 reference

12 December 2020

Controlled comparison of the efficacy and safety of four doses of suriclone, diazepam, and placebo in generalized anxiety disorder.

1 reference

12 December 2020

F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential.

1 reference

12 December 2020

Long-term Diazepam Therapy and Clinical Outcome

1 reference

12 December 2020

Piperazine imidazo[1,5-a]quinoxaline ureas as high-affinity GABAA ligands of dual functionality

1 reference

12 December 2020

Pharmacological and clinical studies of cyclopyrrolones: zopiclone and suriclone.

1 reference

12 December 2020

Guidelines for conducting bridging studies in Alzheimer disease

1 reference

12 December 2020

Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity

1 reference

12 December 2020

Comparison of the effects of the benzodiazepine midazolam and three serotonin antagonists on a consummatory conflict paradigm

1 reference

12 December 2020

Buspirone, a novel nonbenzodiazepine anxiolytic

1 reference

12 December 2020

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam

1 reference

12 December 2020

Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings.

1 reference

12 December 2020

Effects of combined alcohol and benzodiazepine: A review

1 reference

12 December 2020

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

1 reference

12 December 2020

The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalized anxiety disorder (GAD): single site findings from a multicenter trial.

1 reference

12 December 2020

Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings

1 reference

12 December 2020

Generalized anxiety disorder: new concepts and psychopharmacologic therapies

1 reference

12 December 2020

Differential sensitivity to the effects of psychotropic drugs: psychotics vs normals; Asian vs Western populations.

1 reference

12 December 2020

Adverse effects of benzodiazepines

1 reference

12 December 2020

Benzodiazepines: use, abuse, and consequences

1 reference

12 December 2020

Benzodiazpine withdrawal effects

1 reference

12 December 2020

Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders

1 reference

12 December 2020

The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel

1 reference

12 December 2020

Current treatments of the anxiety disorders in adults

1 reference

12 December 2020

Generalized anxiety disorder: nature and course

1 reference

12 December 2020

Cholecystokinin peptides, dopamine and schizophrenia--a review

1 reference

12 December 2020

Cholecystokinin potentiates dopamine inhibition of mesencephalic dopamine neurons in vitro.

1 reference

12 December 2020

Controlled discontinuation of benzodiazepine treatment for patients with panic disorder.

1 reference

12 December 2020

Benzodiazepine treatment of panic and agoraphobic symptoms: use, dependence, toxicity, abuse

1 reference

12 December 2020

Placebo-controlled study of gabapentin treatment of panic disorder

1 reference

12 December 2020

Adverse events in placebo-treated patients with generalized anxiety disorder

1 reference

12 December 2020

Benzodiazepine Dependence A Review of the Evidence

1 reference

12 December 2020

1-(2-Pyrimidinyl)-piperazine may alter the effects of the 5-HT1A agonists in the learned helplessness paradigm in rats

1 reference

12 December 2020

Single-site findings in a study of the safety and efficacy of a CCKB receptor antagonist, CI-988, in the treatment of generalized anxiety disorder

1 reference

12 December 2020

A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial

1 reference

12 December 2020

Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxiety

1 reference

12 December 2020

Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety

1 reference

12 December 2020

Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial

1 reference

12 December 2020

NKP608: a selective NK-1 receptor antagonist with anxiolytic-like effects in the social interaction and social exploration test in rats.

1 reference

12 December 2020

The clinical course and long-term management of generalized anxiety disorder.

1 reference

12 December 2020

Mixed anxiety and depression: clinical implications

1 reference

12 December 2020

The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety

1 reference

12 December 2020

One-year follow-up of anxious patients treated with diazepam.

1 reference

12 December 2020

Stressful life events and the onset of a generalized anxiety syndrome.

1 reference

12 December 2020

Association of road-traffic accidents with benzodiazepine use.

1 reference

12 December 2020

Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression

1 reference

12 December 2020

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder

1 reference

12 December 2020

Paroxetine efficacy in the treatment of generalized anxiety disorder

1 reference

12 December 2020

Opioid and benzodiazepine tolerance and dependence: application of theory to critical care practice

1 reference

12 December 2020

Acute effects of neuroleptics on unmedicated schizophrenic patients and controls.

1 reference

12 December 2020

Disinhibitory reactions to benzodiazepines: a review

1 reference

12 December 2020

Mortality of patients dependent on benzodiazepines.

1 reference

12 December 2020

Relative abuse liability of diazepam and oxazepam: behavioral and subjective dose effects.

1 reference

12 December 2020

Comparison of the anticonflict effect of buspirone and its major metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in rats.

1 reference

12 December 2020

10.2165/00003495-200262110-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

0 references

1 reference